Clinical Expert Commentaries  

Clinical Expert Commentaries   published on December 5, 2018
Dr. Sanchez outlines the standardized pathway approach in patients with pancreatic cancer, including the benefits and challenges.

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Ipsen, and Merck & Co., Inc.
Clinical Expert Commentaries   published on November 7, 2018
In this activity, Dr. O'Reilly discusses the key findings from two phase 3 studies that looked at adjuvant and neoadjuvant treatment approaches for different types of patients with pancreatic cancer.

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Ipsen, and Merck & Co., Inc.
Clinical Expert Commentaries   published on September 19, 2018
In this activity, Dr. Emanuel Petricoin outlines the Know Your Tumor Program, including how the program is making a difference in the care of patients with pancreatic cancer. 

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Ipsen, and Merck & Co., Inc.
Clinical Expert Commentaries   published on March 7, 2018
Join Dr. Philip as he covers the LAPACT trial, the phase II trial of nab-paclitaxel and gemcitabine, including quality of life results.

Visit 2017 ESMO Meeting Highlights in Pancreatic Cancer to claim CE credit
Clinical Expert Commentaries   published on February 14, 2018
In this video, Dr. Hecht discusses a new immunotherapy, AM0010, in an expansion cohort of a phase I trial for patients who had pancreatic ductal adenocarcinoma.

Visit 2017 ESMO Meeting Highlights in Pancreatic Cancer to claim CE credit
Clinical Expert Commentaries   published on January 24, 2018
Dr. Bullock discusses the results from the phase II HALO-202 study of PEGPH20 plus nab-paclitaxel and gemcitabine vs. nab-paclitaxel and gemcitabine alone in patients with untreated mPDA.

Visit 2017 ESMO Meeting Highlights in Pancreatic Cancer to claim CE credit
Clinical Expert Commentaries   published on July 26, 2017
Dr. Stuart Goldberg discusses a patient survey tool that helps determine the best time to initiate end-of-life care discussions with your terminal cancer patients.

Results 1 - 7 of 7

MediCom Worldwide, Inc. would like to thank Celgene Corporation for their educational support of PartnersinPancreaticCancer.com.

©2020 MediCom Worldwide, Inc. All rights reserved